Mr. Rebecca Greco reports

STAGEZERO LIFE SCIENCES PROVIDES AN UPDATE ON APPLICATION FOR MANAGEMENT CEASE TRADE ORDER

Further to Stagezero Life Sciences Ltd.'s press release of April 2, 2024, the Ontario Securities Commission (OSC) has denied the company's application for a voluntary management cease trade order (MCTO), as the company does not meet the criteria for an MCTO.

The company filed the application for a voluntary MCTO with the OSC due to an anticipated delay in filing its audited annual financial statements, and management's discussion and analysis, for the financial year ended Dec. 31, 2023, and the chief executive officer and chief financial officer certificates, all as required by National Instrument 51-102 -- Continuous Disclosure Obligations and National Instrument 52-109 -- Certification of Disclosure in Issuers' Annual and Interim Filings (collectively, the documents). The documents are required to be filed by April 2, 2024. As a consequence, if the documents are not filed by the filing deadline, the OSC may impose a failure-to-file cease trade order (FFCTO).

The company continues to work diligently and expeditiously with all of its auditors and expects to file the documents as soon as possible, with a current expectation of before or by May 31, 2024.

About Stagezero Life Sciences Ltd.

Stagezero is a vertically integrated health care company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC protocol), as well as help patients reduce the risk of developing late-stage disease (AVRT).

The company's next-generation test, Aristotle, is the first ever mRNA multicancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the company's patented technology platform, the Sentinel Principle. The Sentinel Principle has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

The care oncology clinic offers a supervised treatment regimen (the COC protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.

AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. The program includes: a comprehensive on-line health evaluation, blood tests to measure markers of inflammation and metabolism, an in-depth initial physician consultation, regular physician follow-up appointments, and interval screening.

Aristotle, as well as additional cancer diagnostics, is processed at the company's clinical laboratory, Stagezero Life Sciences Inc., a College of American Pathologists-accredited and clinical-laboratory-improvement-amendment-certified high-complexity reference laboratory in Richmond, Va.

We seek Safe Harbor.